Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015', provides an overview of the Onychomycosis (Tinea Unguium)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Onychomycosis (Tinea Unguium) Overview 8 Therapeutics Development 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10 Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11 Onychomycosis (Tinea Unguium) - Therapeutics under Investigation by Universities/Institutes 13 Onychomycosis (Tinea Unguium) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Onychomycosis (Tinea Unguium) - Products under Development by Companies 18 Onychomycosis (Tinea Unguium) - Products under Investigation by Universities/Institutes 19 Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 20 Actavis plc 20 Anacor Pharmaceuticals, Inc. 21 Eisai Co., Ltd. 22 Evolva SA 23 Helix BioMedix, Inc. 24 Mayne Pharma Group Limited 25 Meiji Seika Pharma Co., Ltd. 26 Moberg Pharma AB 27 NAL Pharmaceuticals Ltd. 28 Nihon Nohyaku Co., Ltd. 29 Novabiotics Ltd 30 Nuvo Research Inc. 31 Viamet Pharmaceuticals, Inc. 32 Onychomycosis (Tinea Unguium) - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 albaconazole - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AN-2718 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 E-1224 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ELS-160 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 EV-086 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 HB-1275 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 itraconazole - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 luliconazole - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ME-1111 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 NAL-3216 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 NP-213 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules for Fungal Infections - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 terbinafine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 terbinafine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 VT-1161 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 64 Onychomycosis (Tinea Unguium) - Dormant Projects 70 Onychomycosis (Tinea Unguium) - Discontinued Products 72 Onychomycosis (Tinea Unguium) - Product Development Milestones 73 Featured News & Press Releases 73 Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 73 Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 73 Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 74 May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 75 Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 75 Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap 75 Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting 76 Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin 77 Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015 77 Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 80 Disclaimer 80
List of Tables Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2015 9 Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Comparative Analysis by Unknown Stage Development, H1 2015 17 Products under Development by Companies, H1 2015 18 Products under Investigation by Universities/Institutes, H1 2015 19 Onychomycosis (Tinea Unguium) - Pipeline by Actavis plc, H1 2015 20 Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 21 Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H1 2015 22 Onychomycosis (Tinea Unguium) - Pipeline by Evolva SA, H1 2015 23 Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H1 2015 24 Onychomycosis (Tinea Unguium) - Pipeline by Mayne Pharma Group Limited, H1 2015 25 Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 26 Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2015 27 Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 28 Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H1 2015 29 Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2015 30 Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H1 2015 31 Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 32 Assessment by Monotherapy Products, H1 2015 33 Number of Products by Stage and Target, H1 2015 35 Number of Products by Stage and Mechanism of Action, H1 2015 37 Number of Products by Stage and Route of Administration, H1 2015 39 Number of Products by Stage and Molecule Type, H1 2015 41 Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H1 2015 64 Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2015 70 Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H1 2015 71 Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2015 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
